NCT06202001 2024-04-02Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC PatientsCancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 1/2 Recruiting70 enrolled